SUPERNUS PHARMACEUTICALS, INC. (SUPN) Total liabilities 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) total liabilities at each fiscal year-end, per SEC filings.
$390.9MFY2025 · since FY2016: $117.8M → $390.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $390.9M | +17.6% |
| FY2024 | $332.3M | -6.7% |
| FY2023 | $356.2M | -56.4% |
| FY2022 | $816.3M | -6.5% |
| FY2021 | $873.3M | +15.0% |
| FY2020 | $759.2M | +34.4% |
| FY2019 | $564.9M | +7.6% |
| FY2018 | $524.8M | +234.3% |
| FY2017 | $157.0M | +33.2% |
| FY2016 | $117.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SUPN financial trends
SUPN RevenueSUPN Net incomeSUPN Net marginSUPN Gross profitSUPN Gross marginSUPN Operating incomeSUPN Operating marginSUPN Operating cash flowSUPN Free cash flowSUPN Capital expendituresSUPN Return on equitySUPN Stock buybacksSUPN Dividends paidSUPN Total assetsSUPN Shareholders’ equitySUPN overview →